Sheet1

Document Sample
Sheet1 Powered By Docstoc
					Hematological Malignancies

H-1      Alexander Fefer
         Interleukin-2 in the Treatment of Hematologic Malignancies
         The Cancer Journal from Scientific American, Vol.3, Suppl.1

H-2      Amitabha Mazumder
         Experimental Evidence of Interleukin-2 Activity in Bone Marrow Transplantation
         The Cancer journal from Scientific American, Vol.3, Suppl.1

H-3      Giovanna Meloni, Marco Vignetti, et al.
         Interleukin-2 Therapy in Relapsed Acute Myelogenous Leukemia
         The Cancer Journal from Scientific American 1997, Vol.3, Suppl.1

H-4      Alexander Fefer, Nanette Robinson, et al.
         Interleukin-2 therapy after Bone Marrow of Stem Cell Transplantation for
         Hematologic Malignancies.
         The Cancer Journal from Scientific American 1997, Vol.3, Suppl.1

H-5      Koen van Besien, Kim Margolin, et al
         Activity of Interleukin-2 in Non-Hodgkin’s Lymphoma Following Transplantation
         of Interleukin-2- Activated Autologous Bone Marrow or Stem Cells.
         The Cancer Journal from Scientific American 1997, Vol.3, Suppl.1

H-6      Shimon Slavin, Arnon Nagler, et al.
         Cytokine-Meciated Immunotherapy Following Autologous Bone Marrow
         Transplantation in Lymphoma and Evidence of Interleukin-2-Induced
         Immunomodulation in Allogenic Transplants.
         The Cancer Journal from Scientific American 1997, Vol.3, Suppl.1

H-7      Robert Foa
         Does IL-2 have a role in the Management of Acute Leukemia?
         Jr. of Clin. Oncology, Vol 11, No.9.1993

H-8      J.S.Miller et al.
         Low dose subcutaneous IL-2 after autologous transplantation generates
         Sustained in vivo natural killer cell activity
         Biology of Blood & Transplantation 3 : 34-44(1997)

H-9      K.A. Margolin, et al.
         Autologous bone marrow purging by in situ IL-2 activation of Endogenous Killer cells
         Leukemia (1997), 9, 723-728

H-10     A.Nagler, et al.
         Immunotherapy with rIL-2 & rIFN-α in Lymphoma Patient Postautologous
         Marrow or Stem Cell Transplantation
         Blood, Vol.89 No.11 1997
H-11   H.G.Klingemann, C.J.Eaves, et al.
       Transplantation of patients with high risk acute myeloid leukemia first remission with
       autologous marrow cultured in interleukin-2 followed by Interleukin-2 administration.
       Bone Marrow Transplantation 1994,14;389-396

H-12   F.Lauria, D.Raspadori, et al.
       Immunologic and clinical modifications following Low-dose Subcutaneous administration of
       rIL-2 in non-Hodgkin’s lymphoma Patients after autologous bone marrow transplantation
       Bone Marrow Transplantation(1996) 18.79-85

H-13   D.Raspadori, et al.
       Low dose of rIL-2 after ABMT induce a “ prolonged” immunostimulation of
       NK compartment in high-grade non-Hodgkin’s Lymphomas.
       Ann. Hematol(1995)71:175-179

H-14   A. Nagler, et al.
       Postautologous Immunotherapy with rIL-2 and rIFN-α in Lymphoma Patient
       Blood, Vol.89, No. 11, 1997

H-15   KR Meehan, UN Verma, et al.
       IL-2-Activated hematopoietic stem cell transplantation for Breast Cancer:
       Investigation of dose level with Clinical Correlates
       Bone Marrow Transplantation(1997) 20, 643-351

H-16   Eric L. Sievers, J. Beverly, et al.
       Feasibility, Toxicity and Biologic Response of IL-2 after Consolidation
       Chemotherapy for AML : A report from the Children’s Cancer Group
       Jr. of Clinical Oncology, Vol 16, No.3(March), 1998, 914-919

H-17   Hans Georg Klingemann, et al.
       Role of Postinduction Immunotherapy in AML
       Leukemia(1996) 10, Suppl: 521-522

H-18   H.Bertz, R.Hunaman, et al.
       Successful adoptive immunotherapy for relapse of AML 9 Years after T-Cell Depleted BMT
       British Journal of Haematology, 1998. 103. 563-564

H-19   A.Toren, A.ackerstein, et al
       Role of interleukin-2 human hematological malignancies
       Medicla Oncology (1995) 12, 177-186

H-20   J.Mehta, R.Powles, et al.
       Induction of graft-versus-host disease as immunotherapy of leukemia relapsing
       After allogeneic transplantation: single-center experience of 32 adult patients
       Bone Marrow Transplantation,(1997)20. 129-135
H-21   S.Giralt, S.O’Brien, et al.
       Interferon-α and interleukin-2 as treatment for leukemia relapse after allogeneic
       Bone marrow transplantation
       Cytokines and Molecular Therapy 1995.Vol.1.pp. 115-122

H-22   A.M.Carella, L.Celesti, E.Lerma, et al.
       Stem-cell mobilization for autografting in chronic myeloid leukemia
       Blood Reviews(1997)11, 154-159

H-23   A.Nagler, A.Ackerstein, et al.
       Treatment of Chronic Myelogenous Leukemia with Recombinant Human
       Interleukin-2 and Interferon-α2a
       Journal of Hematotherapy 3:75-82(1994)

H-24   B.A.Pierson, J.S.Miller
       The Role of Autologous Natural Killer Cells in Chronic Myelogenous Leukemia
       Leukemia and Lymphoma, Vol.27.pp.387-399

H-25   F.Dazzi, EJ.Kanfer
       Dual Immunotherapy with Donor Lymphocytes and Interleukin-2 for High-Risk
       Relapsed Leukaemia Following Allogeneic Marrow Transplantation
       Protocol

H-26   Clinical abstracts of the American Society of Hematology 1998(Dec)

H-27   J.E.Cortes, H.M.Kantarjian, et al.
       A Pilot study of IL-2 for Adult patients with AML in first complete Remission
       Cancer. Apr. 1.1999.Vol.85, pp.1505-1513, No.7

H-28   F.Mandelli, S.Capria, M.Vignetti, et al.
       Use of Interleukin-2 in the Management of Haematological malignancies Focus
       on Minimal Residual Disease
       BioDrugs 1999, July 12(1):43-53

H-29   김문규, 김효철, et al.
       급성골수성환아에서 말초조혈모세포 이식 후 Interleukin-2 치료
       대한조혈모세포이식학회지 제 3권 2호 1998

H-30   김문규, 유철주, 조현상, 양창현, 김황민, 강신혜, 김길영, et al.
       소아 급성골수성 백혈병 및 신경모세포종에서 자가조혈모세포이식 후
       저용량 IL-2 치료 및 호산구의 변화
       대한소아혈액종양학회지 제 7권 1호 2000

H-31   Moon Kyu Kim, Yeun Joo Choi, Jae Eun Yu
       Low dose IL-2 Therapy at Allogenic Stem Cell Transplantation to Prevent Relapse
       Abstracts from ISH 2002
H-32   G.Meloni, SM Trisolini, et al.
       How long can we give IL-2 ? Clinical and Immunological Evaluation of AML patients
       after 10 or more years of IL-2 administration
       Leukemia (2002) 16, 2016-2018

H-33   Anthony S. Stein, Margaret R. O'Donnel, et al.
       IL-2 After ASCT for Adult Patients with AML in First Complete Remission
       Journal of Clinical Oncology, Vol. 21, No. 4, 2003, 615-623

H-34   A.Perillo, L. Pierelli, et al.
       Administration of low-dose IL-2 plus G-CSF/EPO early after autologous
       PBSC Transplantation : effects on immune recovery and NK activity
       in Prospective Study in Women with Breast and Ovarian Cancer
       Bone Marrow Transplantation (2002) 30, 571-578

H-35   김문규, 김병주, 최연주
       동종 조혈모세포 이식후 재발방지를 위한 저용량 IL-2 치료
       The Korea Journal of Hematopoietic Cell Transplantation, Vol 7, 2002

H-36   김종태, 배기수, 김문규, 정조원
       다운증후군이 동반된 급성골수성 백혈병에서 항화학요법과 저용량 IL-2를 병용하여
       완치된 환자 1례
       The Korea Journal of Pediatric Hematology-oncology, Vol 8, No 1, 2001

H-37   OF ballester, T. Fang, et al.
       Adoptive immunotherapy with donor lymphocyte infusions and IL-2 after high-dose therapy
       and autologous stem cell rescue for multiple myeloma
       Bone marrow transplantation (2004), 1-5

H-38   Anna Dmoszynska, Martyna Kandefer-Szerszen,et al.
       Influence of Low dose rIL-2 Treatment on Endogenous Cytokine Production,
       Expression of Surface IL-2R and the Level of Soluble IL-2R in Patients with
       Minimal Residual Disease
       Leukemia and Lymphoma, 1999, Vol. 35(3-4), pp. 355-366

H-39   Shimon Slavin, Elizabeth Naparstek, et al.
       Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation
       with donor peripheral blood lymphocytes.
       Experimental Hematology 23: 1553-1562(1995)

H-40   Shimon Slavin, Elizabeth Naparstek, et al.
       Allogeneic cell therapy with donor peripheral blood cells and recombinant human
       interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation
       Blood, Vol.87, No.6 (March 15), 1996: pp 2195-2204

H-41   Francesco Recchia, Sandro De Filipps, et al.
       Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease:
       A phase II study
       International Journal of Oncology 20: 1275-1282, 2002

H-42   Shoshana Morecki, Shoshana Revel-Vilk, et al.
       Immunological evaluation of patients with hematological malignancies receiving ambulatory
       cytokine-mediated immunotherapy with recombinant human interferon-a2b and interleukin-2
       Cancer Immunol Immunother (1992) 35: 401-411

H-43   M.C. Benyunes, C. Massumoto, et al.
       Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy
       after autologous bone marrow transplantation for acute myelogenous leukemia
       Bone Marrow Transplantation 1993; 12: 159-163

H-44   Anna Dmoszynska, Wojciech Legiec, et al.
       Attempted reconstruction of the immune system using low doses of interleukin-2 in
       chronic lymphocytic leukemia patients treated with 2-chlorodeoxyadenosine:
       Results of a pilot study
       Leukemia and Lymphoma, 1999, Vol.34(3-4), pp. 335-340

H-45   Ray C. Pais, Aly Abdel-Mageed, et al.
       Phase I study of recombinant human interleukin-2 for pediatric malignancies:
       Feasibility of outpatient therapy. A pediatric oncology group study
       Journal of Immunotherapy Vo.12, No.2, 1992, pp.138-146

H-46   Norbert Vey, Patrice Viens, et al.
       Clinical and biological effects of gamma interferon and the combination of
       gamma interferon and interleukin-2 after autologous bone marrow transplantation
       Eur Cytokine Netw Vol.8, No.4, December 1997, 389-94

H-47   Anthony S. Stein, Margaret R. O'Donnel, et al.
       Interleukin-2 after autologous stem-cell transplantation for adult patients
       with aucte myeloid leukemia in first complete remission
       J Clin Oncol Vol.21, No.4(Feb. 15), 2003: pp.615-623
H-48   Peter H. Wiernik, Janice P. Dutcher, et al.
       Polyethylene glycolated interleukin-2 as maintenance theraoy for acute
       myelogenous leukemia in second remission
       American Journal of Hematology 47: 41-44(1994)

H-49   Allen Eng-Juh Yeoh, Thuan-Chong Quah
       Minimal residual disease in childhood acute lymphoblastic leukemia -
       asian perspective
       JAMA SEA Jan/Feb, 1998, p9-11

H-50   Kyung Ha Ryu, Hyo Seop Ahn, et al.
       Autologous stem cell transplantation for the treatment of neuroblastoma in Korea
       Journal of Korean Medical Science, Vol.18, No.2, April 2003, pp242-247
H-51   Didier Blaise, Michel Attal, et al.
       Randomized study of recombinant interleukin-2 after autologous bone
       marrow transplantation for acute leukemia in first complete remission
       Eur. Cytokine Netw., Vol.11, No.1, March 2000, 91-7
nsplantation




nsplantation




genous Killer cells
 st remission with
-2 administration.



aneous administration of
marrow transplantation




er T-Cell Depleted BMT




mia relapsing
er allogeneic




 High-Risk




ancies Focus




revent Relapse
n of AML patients




-2를 병용하여




 after high-dose therapy




nsplantation




 binant human
w transplantation



esidual disease:
ies receiving ambulatory
ron-a2b and interleukin-2



nsolidative immunotherapy
us leukemia



f interleukin-2 in




transplantation




toma in Korea

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:5
posted:11/12/2011
language:English
pages:11